Veracyte (VCYT) Accumulated Expenses (2012 - 2026)

Veracyte has disclosed Accumulated Expenses across 15 years of filings, most recently posting $43.1 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $43.1 million, up 20.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $43.1 million (up 20.04% YoY), and the FY2025 annual result was $48.8 million, up 11.35% from the prior year.
• Accumulated Expenses came in at $43.1 million for Q1 2026 at Veracyte, down from $48.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $48.8 million in Q4 2025 to a low of $30.3 million in Q1 2024.
• The 5-year median for Accumulated Expenses is $38.4 million (2023), against an average of $38.9 million.
• Across the five-year window, Accumulated Expenses jumped 137.13% in 2022 and dropped 20.5% in 2023, its largest moves.
• Veracyte's Accumulated Expenses stood at $37.8 million in 2022, then rose by 1.73% to $38.4 million in 2023, then grew by 14.05% to $43.8 million in 2024, then grew by 11.35% to $48.8 million in 2025, then retreated by 11.62% to $43.1 million in 2026.
• The last three Accumulated Expenses figures came in at $43.1 million (Q1 2026), $48.8 million (Q4 2025), and $48.4 million (Q3 2025), per Business Quant data.